{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:11:41Z","timestamp":1785600701992,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS\u2010CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival\/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I\u2010III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0\/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan\u2010Meier and Cox regression) was performed in an ENS\u2010CCA training cohort (TC) and findings internally (ENS\u2010CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS\u2010CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS\u2010CCA and SEER registries were reclassified into group C, respectively. In the ENS\u2010CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (<jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001); patients in group C (HR, 2.53; 95% CI, 1.18\u20105.42; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.017) had a higher risk of death (vs. group A). Findings were validated in the ENS\u2010CCA iVC (HR, 2.93; 95% CI, 2.04\u20104.19; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68\u20102.09; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including \u201cliver metastases: multiple liver lesions, with or without vascular invasion\u201d as an \u201cM1a stage,\u201d is suggested.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.31598","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T02:19:50Z","timestamp":1603073990000},"page":"2311-2325","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":66,"title":["Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System"],"prefix":"10.1097","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[{"name":"Medical Oncology\/Institute of Cancer Sciences,The Christie NHS Foundation Trust\/University of Manchester,Manchester,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Santos\u2010Laso","sequence":"additional","affiliation":[{"name":"Department of Liver and Gastrointestinal Diseases,Biodonostia Health Research Institute,Donostia University Hospital,University of the Basque Country (UPV\/EHU),San Sebastian,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Utpatel","sequence":"additional","affiliation":[{"name":"Institute of Pathology,University of Regensburg,Regensburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaida","family":"La Casta","sequence":"additional","affiliation":[{"name":"Department of Liver and Gastrointestinal Diseases,Biodonostia Health Research Institute,Donostia University Hospital,University of the Basque Country (UPV\/EHU),San Sebastian,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Stock","sequence":"additional","affiliation":[{"name":"Institute of Pathology,University of Regensburg,Regensburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-4950","authenticated-orcid":false,"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[{"name":"BCLC group, Liver Unit,Hospital Cl\u00ednic Barcelona,Barcelona,Spain"},{"name":"National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd),The National Institute of Health Carlos III,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-4120","authenticated-orcid":false,"given":"Jorge","family":"Adeva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Hospital Universitario 12 de Octubre,Madrid,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Folseraas","sequence":"additional","affiliation":[{"name":"7Section of Gastroenterology and the Norwegian PSC Research Center,Department of Transplantation Medicine,Oslo University Hospital,Oslo,Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fabris","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine,University of Padua,Padua,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-0326","authenticated-orcid":false,"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[{"name":"National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd),The National Institute of Health Carlos III,Madrid,Spain"},{"name":"Experimental Hepatology and Drug Targeting (HEVEPHARM) group,University of Salamanca,IBSAL,Salamanca,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Medicine II,Saarland University Medical Centre,Saarland University,Homburg,Germany"},{"name":"Laboratory of Metabolic Liver Diseases,Centre for Preclinical Research,Department of General, Transplant and Liver Surgery,Medical University of Warsaw,Warsaw,Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of General, Transplant and Liver Surgery,Medical University of Warsaw,Warsaw,Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cardinale","sequence":"additional","affiliation":[{"name":"Gastroenterology,Sapienza University of Rome,Rome,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[{"name":"Medical Oncology,The University of Glasgow,Glasgow,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Alvaro","sequence":"additional","affiliation":[{"name":"Gastroenterology,Sapienza University of Rome,Rome,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Evert","sequence":"additional","affiliation":[{"name":"Institute of Pathology,University of Regensburg,Regensburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[{"name":"Department of Liver and Gastrointestinal Diseases,Biodonostia Health Research Institute,Donostia University Hospital,University of the Basque Country (UPV\/EHU),San Sebastian,Spain"},{"name":"National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd),The National Institute of Health Carlos III,Madrid,Spain"},{"name":"IKERBASQUE,Basque Foundation for Science,Bilbao,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[{"name":"Medical Oncology\/Institute of Cancer Sciences,The Christie NHS Foundation Trust\/University of Manchester,Manchester,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS\u2010CCA)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"hep31598-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","year":"2001","journal-title":"Hepatology"},{"key":"hep31598-bib-0002-20250824","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ctrv.2008.11.009","article-title":"Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions","volume":"35","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"hep31598-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty\u2010one\u2010year experience with 564 patients at a single institution","volume":"245","year":"2007","journal-title":"Ann Surg"},{"key":"hep31598-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS\u2010CCA)","volume":"13","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep31598-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.2174\/0929867327666200123090153","article-title":"Clinical and translational research challenges in biliary tract cancers","volume":"27","year":"2020","journal-title":"Curr Med Chem"},{"issue":"Suppl. 1","key":"hep31598-bib-0006-20250824","first-page":"98","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","year":"2019","journal-title":"Liver Int"},{"key":"hep31598-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"P663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"hep31598-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"hep31598-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"issue":"15 Suppl.","key":"hep31598-bib-0010-20250824","article-title":"ABC\u201006 | A randomised phase III, multi\u2010centre, open\u2010label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin\/5\u2010FU chemotherapy (ASC + mFOLFOX) for patients (pts) with locally advanced\/metastatic biliary tract cancers (ABC) previously\u2010treated with cisplatin\/gemcitabine (CisGem) chemotherapy [abstract no. 4003]","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"hep31598-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2017.35.15_suppl.4018","article-title":"A phase II trial of gemcitabine (G), cisplatin (C), and nab\u2010paclitaxel (N) in advanced biliary tract cancers (aBTCs)","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl. 8","key":"hep31598-bib-0012-20250824","first-page":"viii205","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S\u20101 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401\u2010MITSUBA)","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"hep31598-bib-0013-20250824","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium\u201090 radioembolization: a systematic review and pooled analysis","volume":"41","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"hep31598-bib-0014-20250824","first-page":"51","article-title":"Radioembolization plus chemotherapy for first\u2010line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA","volume":"6","year":"2019","journal-title":"Oncol"},{"key":"hep31598-bib-0015-20250824","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi\u2010institutional phase II study of high\u2010dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"hep31598-bib-0016-20250824","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC\u201001, \u201002, and \u201003 clinical trials","volume":"112","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"hep31598-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"issue":"Suppl. 8","key":"hep31598-bib-0018-20250824","first-page":"viii720","article-title":"Updated results from a phase II study of infigratinib (BGJ398), a selective pan\u2010FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"hep31598-bib-0019-20250824","first-page":"v851","article-title":"Ivosidenib in IDH1\u2010mutant, chemotherapy\u2010refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double\u2010blind, placebo\u2010controlled, phase 3 study. ESMO 2019 Congress","volume":"30","year":"2019","journal-title":"Ann Oncol"},{"key":"hep31598-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep31598-bib-0024-20250824","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jhbp.86","article-title":"Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan","volume":"21","year":"2014","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"hep31598-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/carcin\/bgz120","article-title":"Multifocal origin of occupational cholangiocarcinoma revealed by comparison of multilesion mutational profiles","volume":"41","year":"2020","journal-title":"Carcinogenesis"},{"key":"hep31598-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1002\/cncr.24471","article-title":"Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases","volume":"115","year":"2009","journal-title":"Cancer"},{"key":"hep31598-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2010up","volume":"27","year":"2016","journal-title":"Ann Oncol"},{"key":"hep31598-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/cco.2018.07.03","article-title":"Intrahepatic cholangiocarcinoma: the AJCC\/UICC 8th edition updates","volume":"7","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"hep31598-bib-0031-20250824","article-title":"Evaluation and Recommendation of the 8th Edition of American Joint Committee on Cancer (AJCC) Staging System for Intrahepatic Cholangiocarcinoma (ICC) in 820 Patients from the Surveillance, Epidemiology, and End Results (SEER) Database","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"hep31598-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-008-0180-z","article-title":"A proposed staging system for intrahepatic cholangiocarcinoma","volume":"16","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"hep31598-bib-0033-20250824","article-title":"Development and validation of a prognostic score for intrahepatic cholangiocarcinoma","volume":"152","year":"2017","journal-title":"JAMA Surg"},{"key":"hep31598-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement","volume":"17","year":"2015","journal-title":"HPB (Oxford)"},{"key":"hep31598-bib-0035-20250824","first-page":"557","article-title":"Cholangiocarcinoma 2020: next horizon in mechanisms and management. Nat Rev","volume":"17","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"hep31598-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1245\/s10434-019-08192-z","article-title":"ALPPS for locally advanced intrahepatic cholangiocarcinoma: did aggressive surgery lead to the oncological benefit? An international multi\u2010center study","volume":"27","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"hep31598-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/jso.24569","article-title":"Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma","volume":"115","year":"2017","journal-title":"J Surg Oncol"},{"key":"hep31598-bib-0038-20250824","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21037\/hbsn.2016.10.02","article-title":"Staging of intrahepatic cholangiocarcinoma","volume":"6","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"hep31598-bib-0039-20250824","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jhbp.543","article-title":"Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma","volume":"25","year":"2018","journal-title":"J Hepatobiliary Pancreat Sci"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.31598","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.31598","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:05:27Z","timestamp":1756080327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.31598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.31598","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2020-05-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}